| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma (NCT05318339) | Chinese Academy of Medical Sciences | 2022-03-10 |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05014139) | Astellas Pharma Global Development, Inc. | 2021-12-07 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (NCT03410693) | Bayer | 2018-05-31 |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (NCT03288545) | Astellas Pharma Global Development, Inc. | 2017-10-11 |
| A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (NCT03219333) | Astellas Pharma Inc | 2017-10-08 |
| The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (NCT02793128) | UroGen Pharma Ltd. | 2017-04-04 |
| Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract (NCT03051373) | Chinese PLA General Hospital | 2017-04-01 |
| Neoadjuvant Atezolizumab in Localized Bladder Cancer (NCT02451423) | Lawrence Fong | 2016-03-29 |
| A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (NCT02450331) | Hoffmann-La Roche | 2015-10-05 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (NCT02443324) | Eli Lilly and Company | 2015-07-29 |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer (NCT02300610) | H. Lee Moffitt Cancer Center and Research Institute | 2015-02-11 |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (NCT02014337) | Corcept Therapeutics | 2014-01-01 |
| Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (NCT01856101) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2013-02-01 |
| Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer (NCT01529411) | Spanish Oncology Genito-Urinary Group | 2012-02-01 |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors (NCT01478685) | Celgene | 2011-11-29 |
| Tesetaxel for Previously Treated Patients With Bladder Cancer (NCT01215877) | Genta Incorporated | 2010-09-01 |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder (NCT00722553) | Acrotech Biopharma Inc. | 2008-07-01 |
| Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma (NCT00172367) | National Taiwan University Hospital | 2006-01-01 |
| Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure (NCT00109655) | Cell Genesys | 2005-04-01 |
| Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer (NCT04039867) | University of California, Irvine | 2005-01-20 |
| Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer (NCT00101842) | Eli Lilly and Company | 2004-12-01 |
| 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen (NCT00191971) | Eli Lilly and Company | 2004-01-01 |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium (NCT00077688) | Achieve Life Sciences | 2003-11-01 |
| Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract (NCT00127595) | Gustave Roussy, Cancer Campus, Grand Paris | 2002-01-01 |
| Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer (NCT00146276) | Association of Urologic Oncology (AUO) | 2000-07-01 |
| A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder (NCT00001381) | National Cancer Institute (NCI) | 1994-03-01 |
| Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors (NCT07675057) | Eli Lilly and Company | |